Cipla has received final USFDA approval to market Entecavir tablets used for treatment of Hepatitis B infection. The tablets are generic versions of Bristol-Myers Suibb’s Baraclude tablets of the same strength. The tablets are indicated for the treatment of chronic Hepatitis B virus infection. Baraclude tablets and generic equivalents had US sales of approximately USD 206 million for the 12-month period ending October 2016. The product is likely to launched in early 2017.
Company Profile : Cipla Ltd
Leave a Reply